Pharmazac launched the new product Etrozac / etoricoxib.
November 2, 2023CPhI 9-11 October 2018 Madrid, Spain
November 2, 2023Pharmazac launched the new product Petasitis Hybridus (Petagran)

Pharmazac has developed in its laboratories and launched in the Greek pharmaceutical market a nutraceutical, the titrate extract of Petasitis Hybridus in liquid hard gelatin capsules of 70,4 mg P A free, under the trade name Petagran.
Petagran / Petasitis hybridus is effective in reducing the frequency and severity of migraine attracts.
Related News
November 2, 2023
We are investing in our new pharmaceuticals manufacturing site.
Pharmazac is working on its latest investment a new site of 10.000 sq.m for pharmaceuticals manufacturing, in the industrial zone of Keratea near Athens area . […]
November 2, 2023
Pharmazac launched the new product Zaolin/Vinorelbin
Pharmazac launched the new product Zaolin/Vinorelbin the first generic version for oral use ( soft gelatin caps) in Greece. Zaolin/Vinorelbin is a chemotherapy drug used to […]
November 2, 2023
We are exhibiting and partnering
With Covid-19 on the way of most of our exhibiting activities, Pharmazac has joined in 2020 the largest pharmaceutical partnering events and has participated in more […]
November 2, 2023
We are becoming a manufacturer and key player in radiopharmaceuticals
We are becoming a manufacturer and key player in radiopharmaceuticals ! Pharmazac is happy to announce that its radiopharmaceuticals manufacturing unit in the industrial zone of […]
